Other Viral Infections – Pipeline Review, H2 2012

Other Viral Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Viral Infections - Pipeline Review, H2 2012', provides an overview of the Other Viral Infections therapeutic pipeline. This report provides information on the therapeutic development for Other Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Viral Infections. 'Other Viral Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Viral Infections.
- A review of the Other Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Viral Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Viral Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Viral Infections pipeline depth and focus of Other Viral Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Other Viral Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Viral Infections 7
Other Viral Infections Therapeutics under Development by Companies 9
Other Viral Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Other Viral Infections Therapeutics – Products under Development by Companies 16
Other Viral Infections Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Other Viral Infections Therapeutics Development 18
MacroGenics, Inc. 18
GenPhar, Inc. 19
Other Viral Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Ribavirin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Live-Attenuated Chimeric Bovine Human Parainfluenza Type 3 Virus Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cidofovir - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Acetaminophen + Chlorpheniramine + Phenylephrine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
Valomaciclovir - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monocloncal Antibodies For Pathogens - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Other Viral Infections Therapeutics - Dormant Products 34
Other Viral Infections – Product Development Milestones 35
Featured News & Press Releases 35
Jul 23, 2012: Chimerix's Antiviral Compound, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Phase II Study 35
May 05, 2011: IBT Receives NIAID Advanced Technology Phase I SBIR Grant 36
Jan 12, 2011: Inovio Announces Publication Of Preclinical Results Of Chikungunya DNA Vaccine In PLoS Neglected Tropical Diseases 36
Nov 17, 2010: Peregrine Reports Bavituximab Demonstrates Broad Potential In Viral Hemorrhagic Fever Infection Models 37
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 37
Sep 16, 2010: LigoCyte Initiates First Clinical Trial For Bivalent Intramuscular Norovirus Vaccine 39
Sep 10, 2010: Tekmira Initiates Development Of TKM-Ebola 39
Aug 12, 2010: Novavax Announces Positive Results From Preclinical Safety Study Of RSV Vaccine Candidate 39
Jul 19, 2010: Nanoviricides Presents Anti-Ebola Results At Annual Meeting Of American Society For Virology 40
Jun 24, 2010: Crucell Announces Start Of Universal RSV Vaccine Program 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Other Viral Infections, H2 2012 7
Products under Development for Other Viral Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
MacroGenics, Inc., H2 2012 18
GenPhar, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Other Viral Infections Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Other Viral Infections, H2 2012 7
Products under Development for Other Viral Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25